Please provide your email address to receive an email when new articles are posted on . The etanercept biosimilar, LBEC0101, demonstrated equivalent clinical efficacy and comparable safety profile to ...

THOUSAND OAKS, Calif., and RADNOR, Penn., – Results from a study of ENBREL® (etanercept), the only fully human TNF receptor, were presented demonstrating significant inhibition in the progression of ...

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., JUNE 19, 2003 – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today ...

WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs. In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed ...

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...

On Monday, May 17 th, the U.S. Supreme Court decided not to take up Sandoz’s petition for the Court to review previous lower court decisions on the launch of its biosimilar product. This included a ...

An appeals court ruling means biosimilar competition won't affect U.S. Enbrel sales for a long time. Enbrel is a tumor necrosis factor (TNF) inhibitor that earned its first FDA approval all the way ...

Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept). This patent is owned by Hoffman-La Roche Inc.

Last week, the Federal Circuit denied Sandoz’s petition for an en banc rehearing of its precedential July 1st panel decision upholding two of Immunex’s patents covering Enbrel®. As explained in the ...

Amgen last summer scored a major patent win to defend its blockbuster immunology med Enbrel from impending biosimilar competition. Now, Novartis is challenging that ruling in appeals court, but ...

Every time Charlotte publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...